LENZ Therapeutics (LENZ) Common Equity (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Common Equity data on file, last reported at $246.5 million in Q1 2026.

• Common Equity for Q1 2026 came in at $246.5 million, up 28.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $246.5 million (up 28.37% YoY), and the FY2025 annual result was $284.3 million, up 39.32% from the prior year.
• Common Equity slipped to $246.5 million in Q1 2026 per LENZ's latest filing, from $284.3 million in the prior quarter.
• Over five years, Common Equity peaked at $361.3 million in Q1 2022 and troughed at -$92.7 million in Q4 2023.
• A 5-year average of $157.4 million and a median of $198.2 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2023 and 2024: Common Equity plunged 283.6% in 2023, then soared 640.29% in 2024.
• A 5-year view of Common Equity shows it stood at -$24.2 million in 2022, then sank by 283.6% to -$92.7 million in 2023, then surged by 320.13% to $204.1 million in 2024, then jumped by 39.32% to $284.3 million in 2025, then retreated by 13.31% to $246.5 million in 2026.
• Business Quant data shows LENZ's Common Equity at $246.5 million in Q1 2026, $284.3 million in Q4 2025, and $193.9 million in Q3 2025.